Literature DB >> 16091253

Approach to the treatment-experienced patient.

Joel E Gallant1.   

Abstract

Failure of antiretroviral therapy can occur for a variety of reasons, but is often caused by or accompanied by drug resistance, which increases with continued time on nonsuppressive, failing regimens. Response to early virologic failure on an initial regimen may be associated with minimal or no resistance and can sometimes be managed simply by reinforcing adherence or by intensifying therapy. Resistance testing is an important tool for managing patients who are failing therapy; it should be used in most cases to guide selection of the next regimen. For patients with extensive treatment experience and drug resistance, there are a variety of approaches that have been suggested when fully suppressive options are not available. Clinicians caring for such patients must balance the benefit of slower progression associated with continued therapy against the risk of increasing drug resistance and loss of future treatment options.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16091253     DOI: 10.1007/s11904-005-0023-5

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  43 in total

1.  Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance.

Authors:  M Mouroux; A Yvon-Groussin; G Peytavin; C Delaugerre; M Legrand; P Bossi; B Do; A Trylesinski; B Diquet; E Dohin; J F Delfraissy; C Katlama; V Calvez
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

2.  A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.

Authors:  Calvin J Cohen; Susan Hunt; Michael Sension; Charles Farthing; Marcus Conant; Susan Jacobson; Jeffrey Nadler; Werner Verbiest; Kurt Hertogs; Michael Ames; Alex R Rinehart; Neil M Graham
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

3.  Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.

Authors:  Dale J Kempf; Martin S King; Barry Bernstein; Paul Cernohous; Eric Bauer; Jennifer Moseley; Kai Gu; Ann Hsu; Scott Brun; Eugene Sun
Journal:  J Infect Dis       Date:  2003-12-31       Impact factor: 5.226

4.  Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

Authors:  D Descamps; P Flandre; V Calvez; G Peytavin; V Meiffredy; G Collin; C Delaugerre; S Robert-Delmas; B Bazin; J P Aboulker; G Pialoux; F Raffi; F Brun-Vézinet
Journal:  JAMA       Date:  2000-01-12       Impact factor: 56.272

5.  Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens.

Authors:  J S Montaner; P R Harrigan; N Jahnke; J Raboud; E Castillo; R S Hogg; B Yip; M Harris; V Montessori; M V O'Shaughnessy
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

6.  Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy.

Authors:  Soo Aleman; Karin Söderbärg; Ubaldo Visco-Comandini; Gisela Sitbon; Anders Sönnerborg
Journal:  AIDS       Date:  2002-05-03       Impact factor: 4.177

7.  Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation.

Authors:  J M Raboud; S Rae; R S Hogg; B Yip; C H Sherlock; P R Harrigan; M V O'Shaughnessy; J S Montaner
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

8.  Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.

Authors:  Robert T Schooley; Peter Ruane; Robert A Myers; Gildon Beall; Harry Lampiris; Daniel Berger; Shan-Shan Chen; Michael D Miller; Erica Isaacson; Andrew K Cheng
Journal:  AIDS       Date:  2002-06-14       Impact factor: 4.177

Review 9.  Genotypic testing for human immunodeficiency virus type 1 drug resistance.

Authors:  Robert W Shafer
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

10.  Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.

Authors:  Richard Colonno; Ronald Rose; Colin McLaren; Alexandra Thiry; Neil Parkin; Jacques Friborg
Journal:  J Infect Dis       Date:  2004-04-27       Impact factor: 5.226

View more
  1 in total

1.  Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.

Authors:  Kit N Simpson; Walter J Jones; Rukmini Rajagopalan; Birgitta Dietz
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.